NEOADJUVANT PUBLICATIONS & ABSTRACTS

Neoadjuvant data


Neoadjuvant publications

Evidence / Neoadjuvant

DNA Repair Deficiency Biomarkers and the 70-Gene Ultra-High Risk Signature as Predictors of Veliparib/Carboplatin Response in the I-SPY 2 Breast Cancer Trial

PUBLICATION: NPJ Breast Cancer. 2017 Aug 25;3:31. doi: 10.1038/s41523-017-0025-7. AUTHORS: Wolf D.M., Yau C., Sanil A., Glas A., Petricoin E., Wulfkuhle J., Severson T.M., Linn S., Brown-Swigart L., Hirst G., Buxton M., DeMichele A., Hylton N., Symmans F., Yee D., Paoloni M., Esserman L., Berry D., Rugo H., Olopade O., Read More

Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping

PUBLICATION: Annals of Surgical Oncology; March 2017, Volume 24, Issue 3; pp 669–675. AUTHORS: Pat Whitworth, Peter Beitsch, Angela Mislowsky, James V. Pellicane, Charles Nash, Mary Murray, Laura A. Lee, Carrie L. Dul, Michael Rotkis, Paul Baron, Lisette Stork-Sloots, Femke A. de Snoo, Jennifer Beatty ABSTRACT: Hormone receptor-positive (HR+) tumors Read More

Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures

PUBLICATION: Ann Surg Oncol (2016) 23: 3317. https://doi.org/10.1245/s10434-016-5329-6. AUTHORS: Peter Beitsch, Pat Whitworth, Paul Baron, James Pellicane, Tina Treece, Erin Yoder, Mark Gittleman, NBRST Investigators Group SUMMARY: This substudy showed that NAT significantly altered the genomic signature of the patient's breast cancer compared with the patient's pre-treatment genomic profile. These Read More

Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy

PUBLICATION: Ann Surg Oncol (2016) 23: 1522. https://doi.org/10.1245/s10434-015-5030-1. AUTHORS: Paul Baron, Peter Beitsch, Danielle Boselli, James Symanowski, James V. Pellicane, Jennifer Beatty, Paul Richards, Angela Mislowsky, Charles Nash, Laura A. Lee, Mary Murray, Femke A. de Snoo, Lisette Stork-Sloots, Mark Gittleman, Stephanie Akbari, Pat Whitworth SUMMARY: We found that although Read More

Molecular Subtyping Predicts Pathologic Tumor Response in Early-Stage Breast Cancer Treated with Neoadjuvant Docetaxel Plus Capecitabine with or without Trastuzumab Chemotherapy

PUBLICATION: Med Oncol. (2014) 31: 163. https://doi.org/10.1007/s12032-014-0163-9. AUTHORS: Soley Bayraktar, Melanie Royce, Lisette Stork-Sloots, Femke de Snoo, Stefan Glück SUMMARY: The overall pCR plus npCR rate was 25 % (30/122). Stratified by BluePrint/MammaPrint, patients of HER2 type had the best response (59 %), while luminal A (7 %) and B Read More

Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

PUBLICATION: Annals of Surgical Oncology; October 2014, Volume 21, Issue 10; pp 3261–3267. AUTHORS: Pat Whitworth, MD; Lisette Stork-Sloots, MSc; Femke A. de Snoo, MD, PhD; Paul Richards, MD; Michael Rotkis, MD; Jennifer Beatty, DO; Angela Mislowsky, MD; James V. Pellicane, MD; Bichlien Nguyen, MD; Laura Lee, MD; Charles Nash, Read More

Molecular Subtyping of Early-Stage Breast Cancer Identifies a Group of Patients Who Do Not Benefit from Neoadjuvant Chemotherapy

PUBLICATION:  Breast Cancer Res Treat. 2013 Jun;139(3):759-67. doi: 10.1007/s10549-013-2572-4. AUTHORS:  Glück S., de Snoo F., Peeters J., Stork-Sloots L., Somlo G. ABSTRACT: The aim of this study was to analyze the correlation between the pathologic complete response (pCR) rate after neoadjuvant chemotherapy and long-term outcome (distant metastases-free survival [DMFS]) in Read More